Press Releases

May 18th, 2023

HemoShear Therapeutics Participates in Piper Sandler Symposium

Read More »
November 17th, 2022

HemoShear Therapeutics to Participate in Piper Sandler Healthcare Conference

Read More »
October 18th, 2022

HemoShear Therapeutics to Participate in SVB Leerink Securities Biopharma Private Company Connect

Read More »
September 21st, 2022

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline

Read More »
August 25th, 2022

HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer

Read More »
August 10th, 2022

HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda

Read More »
December 14th, 2021

HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer

Read More »
November 16th, 2021

HemoShear Identifies Second Target to Treat Nash for Takeda

Read More »
September 21st, 2021

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

Read More »
July 22nd, 2021

HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
April 21st, 2021

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Read More »
March 31st, 2021

Molecular Genetics and Metabolism Publishes Primary Pharmacology Data Supporting HemoShear’s HST5040 as a Potential Treatment for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
View More +

Contact

info@hemoshear.com

HemoShear Therapeutics, Inc.
501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902